Otoimmün Büllöz Hastalıklar

Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunologic Research. 2018;66(2):255-270. doi:10.1007/s12026-018-8986-7

Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320-332. doi:10.1016/S0140-6736(12)61140-4

Mahajan A, Treister NS, Ma KS, et al. Risk of malignancies and all-cause mortality in patients with pemphigus: A longitudinal cohort study. Journal of American Academy of Dermatology. 2026;94(6):1764-1767. doi:10.1016/j.jaad.2026.01.057

Albadri Z, Häbel H, Thorslund K, et al. Increased Mortality in Patients with Bullous Pemphigoid: A Nationwide Population-based Cohort Study of 5,738 Patients in Sweden. Acta Dermato-Venereologica. 2026;106:adv44309. Published 2026 May 28. doi:10.2340/actadv.v106.44309

Rashid H, Meijer JM, Bolling MC, et al. Insights into clinical and diagnostic findings as well as treatment responses in patients with mucous membrane pemphigoid: A retrospective cohort study. Journal of American Academy of Dermatology. 2022 Jul;87(1):48–55. doi:10.1016/j.jaad.2021.11.061

Lamberts A, Meijer JM, Pas HH, et al. Nonbullous pemphigoid: Insights in clinical and diagnostic findings, treatment responses, and prognosis. Journal of American Academy of Dermatology. 2019;81(2):355-363. doi:10.1016/j.jaad.2019.04.029

Daltaban Ö, Özçentik A, Akman Karakaş A, et al. Clinical presentation and diagnostic delay in pemphigus vulgaris: A prospective study from Turkey. Journal of oral pathology & medicine. 2020;49(7):681-686. doi:10.1111/jop.13052

Aktan Ş, Durdu M. Otoimmün Büllöz Hastalıkların Etyopatogenezi. In: Uzun S, Durdu M, Kaya Tİ, Aktan Ş (eds). Otoimmün Büllöz Hastalıklar. 1st ed. Ankara: Galenos Yayınevi; 2017. p. 15.

Rosi-Schumacher M, Baker J, Waris J, et al. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Frontiers Immunology. 2023;14:1159351. Published 2023 Apr 25. doi:10.3389/fimmu.2023.1159351

Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Archives of Dermatological Research. 2015;307(4):291-298. doi:10.1007/s00403-014-1531-1

Yayli S, Harman M, Baskan EB, et al. Epidemiology of Pemphigus in Turkey: One-year Prospective Study of 220 Cases. Acta Dermatovenerologica Croatica. 2017;25(3):181-188.

Durdu M, Bozca BC, Enli S, et al. A multicentre prospective analysis of the incidence of pemphigoid diseases in Turkey. Australasian Journal of Dermatology. 2021;62(4):e496-e503. doi:10.1111/ajd.13731

Kridin K, Ludwig RJ. The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. Frontiers in Medicine. 2018;5:220. Published 2018 Aug 20. doi:10.3389/fmed.2018.00220

Mahoney MG, Wang Z, Rothenberger K, et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. The Journal of Clinical Investigation. 1999;103(4):461-468. doi:10.1172/JCI5252

Ishii N, Ishida-Yamamoto A, Hashimoto T. Immunolocalization of target autoantigens in IgA pemphigus. Clinical and Experimental Dermatology. 2004;29(1):62-66. doi:10.1111/j.1365-2230.2004.01436.x

Kim JH, Kim SC. Paraneoplastic Pemphigus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa. Frontiers in Immunology. 2019;10:1259. Published 2019 Jun 4. doi:10.3389/fimmu.2019.01259

Moro F, Sinagra JLM, Salemme A, et al. Pemphigus: trigger and predisposing factors. Frontiers in Medicine. 2023;10:1326359. Published 2023 Dec 27. doi:10.3389/fmed.2023.1326359

Zou M, Feng X, Zhan K, et al. Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review. International Journal of Dermatology. 2026;65(7):1420-1430. doi:10.1111/ijd.70362

Hull C. Dermatitis Herpetiformis. In: Zone JJ, Ofori AO, (eds). UpToDate. Waltham, MA: Wolters Kluwer; [2024] [2026 june 30]. Available from: https://www.uptodate.com/contents/dermatitis-herpetiformis

van der Wier G, Jonkman MF, Horváth B. Pemphigus Vulgaris. In: Horváth B, (ed). Autoimmune Bullous Diseases: Text and Review. Cham: Springer International Publishing; 2022. p. 65–76. Available from: https://doi.org/10.1007/978-3-030-91557-5_8

Uzun S. Pemfigus. In: Uzun S, Durdu M, Kaya Tİ, Aktan Ş (eds). Otoimmün Büllöz Hastalıklar. 1st ed. Ankara: Galenos Yayınevi; 2017. p. 71.

Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Archives of Dermatology. 1996;132(2):203-212.

Hertl M, Sitaru C. Pathogenesis, clinical manifestations, and diagnosis of pemphigus. In: Zone JJ (ed). UpToDate. Waltham, MA: Wolters Kluwer; [2025] [2026 june 30]. Available from: https://www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus

Maehara L de SN, Jonkman MF, Horváth B. Pemphigus Foliaceus. In: Horváth B (ed). Autoimmune Bullous Diseases: Text and Review. Cham: Springer International Publishing; 2022. p. 77–86. Available from: https://doi.org/10.1007/978-3-030-91557-5_9

Meijer JM, Lamberts A, Terra JB. Pemphigoid Diseases Affecting the Skin. In: Horváth B (ed). Autoimmune Bullous Diseases: Text and Review. Cham: Springer International Publishing; 2022. p. 107–20.

Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Archives of Dermatology. 2002;138(7):903-908. doi:10.1001/archderm.138.7.903

Lipozenčić J, Ljubojevic S, Bukvić-Mokos Z. Pemphigoid gestationis. Clinics in Dermatology. 2012;30(1):51-55. doi:10.1016/j.clindermatol.2011.03.009

Meijer JM, Rashid H, Terra JB. Mucous Membrane Pemphigoid. In: Horváth B (ed). Autoimmune Bullous Diseases. Cham: Springer International Publishing; 2022 [cited 2023 May 7]. p. 121–9. Available from: https://link.springer.com/10.1007/978-3-030-91557-5_15

Schmidt E, Cardones ARG. Linear IgA bullous dermatosis: Pathogenesis, clinical features, and diagnosis. In: Zone JJ, Ofori AO (eds). UpToDate. Waltham, MA: Wolters Kluwer; [2026] [2026 june 30]. Available from: https://www.uptodate.com/contents/linear-iga-bullous-dermatosis-pathogenesis-clinical-features-and-diagnosis

Lipsker D. Bullous systemic lupus erythematosus. In: Callen JP, Ofori AO, editors. UpToDate. Waltham, MA: Wolters Kluwer; [2025] [2026 june 30]. Available from: https://www.uptodate.com/contents/bullous-systemic-lupus-erythematosus.

Woodley DT, Chen M, Kim G. Epidermolysis bullosa acquisita. In: Zone JJ, Ofori AO (eds). UpToDate. Waltham, MA: Wolters Kluwer; [2026] [2026 june 30]. Available from: https://www.uptodate.com/contents/epidermolysis-bullosa-acquisita

Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of European Academy of Dermatology and Venereology. 2020;34(9):1900-1913. doi:10.1111/jdv.16752

Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of European Academy of Dermatology and Venereology. 2022;36(10):1689-1704. doi:10.1111/jdv.18220

Hull C, Zone JJ. Approach to the patient with cutaneous blisters. In: Stratman E, Ofori AO (eds). UpToDate. Waltham, MA: Wolters Kluwer; [2026] [2026 june 30]. Available from: https://www.uptodate.com/contents/approach-to-the-patient-with-cutaneous-blisters

Hertl M, Geller S. Initial management of pemphigus vulgaris and pemphigus foliaceus. In: Zone JJ, Ofori AO (eds). UpToDate. Waltham, MA: Wolters Kluwer; [2026] [2026 june 30]. Available from: https://www.uptodate.com/contents/initial-management-of-pemphigus-vulgaris-and-pemphigus-foliaceus